摘要
微血管侵犯是肝细胞肝癌患者预后不良的危险因素,通常依靠术后病理检测明确。目前对于伴有微血管侵犯的肝细胞肝癌患者其术后辅助治疗方面缺乏充分的临床证据。索拉非尼是一种多激酶抑制剂,主要用于用于无法手术或伴有远处转移的晚期肝细胞肝癌患者。本文将对索拉非尼用于伴有微血管侵犯的肝细胞肝癌患者的术后辅助治疗方面的研究进展进行简要介绍。
Microvascular invasion is a risk factor for poor prognosis in patients with hepatocellular carcinoma,and is usually determined by postoperative pathological examination.There is currently insufficient clinical evidence for postoperative adjuvant therapy in hepatocellular carcinoma patients with microvascular invasion.Sorafenib is a multi-kinase inhibitor used primarily in patients with advanced hepatocellular carcinoma who are inoperable or have distant metastases.This article will briefly introduce the research progress of sorafenib for postoperative adjuvant therapy in patients with hepatocellular carcinoma with microvascular invasion.
作者
毕新宇
BI Xin-yu(Department of Hepatobiliary Surgery,National Cancer Center/Cancer Hospital,Chinese Academy of Medicai Sciencee and Pekine Union Medicai College,Beijing 100021)
出处
《肝癌电子杂志》
2019年第1期1-3,共3页
Electronic Journal of Liver Tumor
基金
中国传染病国家重点项目,项目编号:2017ZX10201021-007-003
关键词
肝细胞肝癌
微血管侵犯
索拉非尼
辅助治疗
Hepatocellular Carcinoma
Microvascular invasion
Sorafenib
Adjuvant treatment
